DSpace Repository

Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma

Show simple item record

dc.contributor.author Aydogdu, I.
dc.contributor.author Koc, H.
dc.contributor.author Ilhan, O.
dc.contributor.author Gurman, G.
dc.contributor.author Akan, H.
dc.contributor.author Beksac, M.
dc.contributor.author Konuk, N.
dc.contributor.author Uysal, A.
dc.contributor.author Ozerol, E.
dc.date.accessioned 2022-10-06T09:37:19Z
dc.date.available 2022-10-06T09:37:19Z
dc.date.issued 1997
dc.identifier.issn 00176559 (ISSN)
dc.identifier.uri http://hdl.handle.net/11616/62961
dc.description.abstract In recent years, more effective and less toxic treatment protocols have been developed to increase the cure rates in intermediate and high grade non- Hodgkin's lymphoma (NHL). This study was undertaken to investigate the efficacy and toxicity of MINE (ifosfamide, mesna, mitoxantrone and etoposide) combination chemotherapy in patients with intermediate and high grade NHL. Twenty-one patients (16 male, 5 female; age between 26 and 70 years) with NHL were included in the study. An overall response rate of 73% and complete response rate of 56% were achieved and survival rate for responding patients was 80% at the 48th month. Side effects including mild myelosuppression, nausea/vomiting and alopecia were observed. MINE combination seems to be effective and well tolerated without significant toxicity as a first-line therapy in patients with intermediate or high grade NHL.
dc.source Haematologia
dc.title Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record